





On the 23rd July we will say goodbye and good luck to our wonderful senior Medicines Management technician Paula Whitehurst as she leaves us for pastures new at Doncaster CCG.

Paula is one of the longest serving members of the Medicines Management team having started working for Rotherham PCT in 2003.

During her time with us, Paula has mainly worked in and around the Rother Valley South locality. She has seen the localities change, the PCT close and the CCG begin. Over the years Paula has had a leading role on a number of projects, including the setup of the blood glucose meter formulary, overseeing the operation of the wound care service and played a huge role in patient engagement on Medicines Management work streams.



Paula has been an integral part of the Medicines Management Team and will be greatly missed. I know you will join with us to say a massive THANK YOU and good luck.

Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality seen in CARES study.

Febuxostat (Adenuric) is a non-purine, xanthine oxidase inhibitor licensed for the treatment of chronic hyperuricaemia in adults, in whom urate deposition has already occurred (including a history, or presence of tophus and/or gouty arthritis).

The publication of the phase IV clinical study (CARES) <u>here</u> has prompted the manufacturer, in agreement with the European medicines Agency and Medicines and Health products Regulatory Agency (MHRA) to send out a letter to healthcare professionals on the 27th June 2019 stating:

- In patients with gout and a history of major cardiovascular (CV) disease, a significantly higher risk for all-cause mortality and for CV-related death was observed in patients treated with febuxostat compared with patients treated with allopurinol.
- Treatment with febuxostat in patients with pre-existing major CV disease (e.g. MI, stroke or unstable angina) should be avoided unless no other therapy options are appropriate.

A small amount of prescribing of febuxostat occurs in Rotherham (see table below) and clinicians are asked to bear this information in mind when reviewing these patients.

| Febuxostat prescribing March - April 2019 | | | |
|---|-------|--------------------------------|-------|
| Practice | Items | Practice | Items |
| MORTHEN ROAD GROUP PRACTICE | 26 | VILLAGE SURGERY | 8 |
| DINNINGTON GROUP PRACTICE | 24 | BROOM LANE MEDICAL CENTRE | 7 |
| MARKET SURGERY | 22 | STAG MEDICAL CENTRE | 6 |
| MANOR FIELD SURGERY | 21 | SWALLOWNEST HEALTH CENTRE | 6 |
| THE MAGNA GROUP PRACTICE | 19 | WOODSTOCK BOWER GROUP PRACTICE | 6 |
| WICKERSLEY HEALTH CENTRE | 17 | GATEWAY PRIMARY CARE | 5 |
| GREENSIDE SURGERY | 16 | ST ANN'S MEDICAL CENTRE | 5 |
| KIVETON PARK MEDICAL PRACTICE | 16 | BROOM VALLEY ROAD SURGERY | 3 |
| CLIFTON MEDICAL CENTRE | 14 | GREASBROUGH MEDICAL CENTRE | 3 |
| CROWN STREET SURGERY | 14 | TREETON MEDICAL CENTRE | 3 |
| BRINSWORTH MEDICAL CENTRE | 9 | HIGH STREET SURGERY | 2 |
| PARKGATE MEDICAL CENTRE | 9 | YORK ROAD SURGERY | 2 |
| THORPE HESLEY SURGERY | 8 | BLYTH ROAD MEDICAL CENTRE | 1 |

Dual prescribing of Memantine and Acetylcholine Esterase Inhibitors (AChEI) from Memory Service

Following on from the updated NICE guidelines (NG97 - Dementia: assessment, management and support for people living with dementia and their carers) clinicians may notice requests for the prescribing of AChEI **and** memantine from the memory service. All dual prescribing should be done in line with the updated SCP and proforma for prescribing in dementia which can be found in the shared care protocol section of the RCCG website here.

Rotherham CCG Current Preferred Brands / Formulations

Below is a table to help illustrate to patients the benefit to the NHS in Rotherham of prescribers choosing our preferred brands/formulations. These preferences are also mirrored on the ScriptSwitch system.

RECOMMENDED PRESCRIBING



| | Clinical Commissioning Group | | |
|---|--|---------------|--|
| DRUG (generic and all other brands) | PREFERRED BRAND / FORMULATION | NHS SAVING | |
| blood glucose testing strips for 2DM only | GlucoRx Nexus / Glucomen Areo Sensor / Accu-Chek Performa Nano test strips | ~ 50% | |
| aripiprazole 30mg OD | aripirazole 2x15mg OD | 75% | |
| Aveeno | Epimax Oatmeal (or Zeroveen) | 81% | |
| buprenorphine 5, 10, 20 patch | Butec | 55% | |
| buprenorphine 35, 52.5, 70 | Bupeaze | 40% | |
| Cialis | generic | 93% | |
| Diprobase | Epimax | 60% | |
| Doublebase | Isomol | 50% | |
| E45 cream | ExoCream | 33% | |
| fentanyl patch | Matrifen (or Mezolar) | 40% | |
| insulin pen needles | GlucoRx / Tricare / BD Viva | ~ 50% | |
| galantamine XL | Gatalin | 50% | |
| isosorbide mononitrate 60mg | Chemydur or Monomil | 67% | |
| melatonin | Circadin MR | ~ lots | |
| mesalazine (incl Asacol) | Octasa | 26% | |
| methylphenidate XL (all generic and brands) | Delmosart | 50% | |
| morphine MR (incl MST) | Zomorph caps | 33% | |
| naproxen EC tabs | naproxen tablets (non EC) | 58% | |
| oxycodone IR caps | Shortec caps | 40% | |
| oxycodone MR tabs | Longtec tabs | 50% | |
| pramipexole MR | Pipexus | 25% | |
| Lyrica (pregabalin) | generic | 96% | |
| procyclidine 5mg tabs | Kemadrin 5mg tabs | 55% | |
| quetiapine MR | Biquelle MR | 56% | |
| ropinirole XL | Repinex XL | 51% | |
| salmeterol MDI or Serevent MDI inhaler | Soltel | 32% | |
| salmeterol/fluticasone combo MDI | Sirdupla / Seretide | - | |
| Stalevo (or generic carbidopa/levodopa/entacapone) | Sastravi (or Stanek) | 50% | |
| tamsulosin MR tablets | MR capsules (generic) | 63% | |
| tiotropium | Braltus | 26% | |
| tolterodine MR /XL caps | Neditol XL | 50% | |
| tramadol MR tabs (100, 150, 200mg) | Marol | ~ lots | |
| venlafaxine MR / XL (75, 150, 225mg) | Vensir | 54% | |

Version 1 - July 2019